XBiotech Statistics
Total Valuation
XBiotech has a market cap or net worth of $52.74 million. The enterprise value is -$52.29 million.
Important Dates
The last earnings date was Thursday, November 12, 2026.
| Earnings Date | Nov 12, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
XBiotech has 30.49 million shares outstanding. The number of shares has increased by 0.02% in one year.
| Current Share Class | 30.49M |
| Shares Outstanding | 30.49M |
| Shares Change (YoY) | +0.02% |
| Shares Change (QoQ) | n/a |
| Owned by Insiders (%) | 36.87% |
| Owned by Institutions (%) | 6.57% |
| Float | 19.25M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 0.41 |
| P/TBV Ratio | 0.44 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio History Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 39.51, with zero debt.
| Current Ratio | 39.51 |
| Quick Ratio | 39.12 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -29.94% and return on invested capital (ROIC) is -250.23%.
| Return on Equity (ROE) | -29.94% |
| Return on Assets (ROA) | -19.72% |
| Return on Invested Capital (ROIC) | -250.23% |
| Return on Capital Employed (ROCE) | -37.72% |
| Weighted Average Cost of Capital (WACC) | 8.35% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$500,977 |
| Employee Count | 52 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, XBiotech has paid $206,000 in taxes.
| Income Tax | 206,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -19.91% in the last 52 weeks. The beta is 0.75, so XBiotech's price volatility has been lower than the market average.
| Beta (5Y) | 0.75 |
| 52-Week Price Change | -19.91% |
| 50-Day Moving Average | 2.04 |
| 200-Day Moving Average | 2.27 |
| Relative Strength Index (RSI) | 33.96 |
| Average Volume (20 Days) | 81,077 |
Short Selling Information
The latest short interest is 315,307, so 1.03% of the outstanding shares have been sold short.
| Short Interest | 315,307 |
| Short Previous Month | 300,908 |
| Short % of Shares Out | 1.03% |
| Short % of Float | 1.64% |
| Short Ratio (days to cover) | 3.74 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -47.49M |
| Pretax Income | -43.38M |
| Net Income | -43.59M |
| EBITDA | -46.23M |
| EBIT | -47.49M |
| Earnings Per Share (EPS) | -$1.43 |
Full Income Statement Balance Sheet
The company has $105.04 million in cash and no debt, with a net cash position of $105.04 million or $3.45 per share.
| Cash & Cash Equivalents | 105.04M |
| Total Debt | n/a |
| Net Cash | 105.04M |
| Net Cash Per Share | $3.45 |
| Equity (Book Value) | 124.07M |
| Book Value Per Share | 4.07 |
| Working Capital | 103.66M |
Full Balance Sheet Cash Flow
In the last 12 months, operating cash flow was -$40.96 million and capital expenditures -$46,000, giving a free cash flow of -$41.00 million.
| Operating Cash Flow | -40.96M |
| Capital Expenditures | -46,000 |
| Depreciation & Amortization | 1.26M |
| Net Borrowing | n/a |
| Free Cash Flow | -41.00M |
| FCF Per Share | -$1.34 |
Full Cash Flow Statement Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
XBiotech does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -0.02% |
| Shareholder Yield | -0.02% |
| Earnings Yield | -82.66% |
| FCF Yield | -75.13% |
Analyst Forecast
| Price Target | n/a |
| Price Target Difference | n/a |
| Analyst Consensus | n/a |
| Analyst Count | n/a |
| Revenue Growth Forecast (3Y) | n/a |
| EPS Growth Forecast (3Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
| Graham Formula Value | n/a |
| Graham Formula Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 1 |